Literature DB >> 18200774

[Effect of calcium channel blocker in combination with an angiotensin II receptor blocker in Japanese patients with hypertension].

Takao Saruta1.   

Abstract

It is hard to achieve antihypertensive goal in daily clinical practice. Combination therapy is mostly applied since antihypertensive therapy with single agent has limitations. Ca channel blocker (CCB), angiotension II receptor blocker (ARB) and angiotensin-converting enzyme (ACE) inhibitor are current mainstream antihypertensives and combination therapy of CCB and ARB is especially applied. CCB shows good antihypertensive effect and has fewer side-effects. On the other hand, ARB inhibits renin-angiotensin system and excels at cardioprotective and renoprotective effect. These combination therapies are vital to achieve antihypertensive goal. In the years ahead, it is necessary to review whether or not there are differences on the effect and medical cost economy even between antihypertensive agents in the same class.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18200774     DOI: 10.2165/00003495-200666991-00008

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  3 in total

Review 1.  Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management.

Authors:  M Behrend
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.

Authors:  Laurence Chan; Shamkant Mulgaonkar; Rowan Walker; Wolfgang Arns; Patrice Ambühl; Ruben Schiavelli
Journal:  Transplantation       Date:  2006-05-15       Impact factor: 4.939

3.  Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.

Authors: 
Journal:  Lancet       Date:  1995-05-27       Impact factor: 79.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.